CJC-1295 w/ DAC (5mg)
Table of Contents
Quickstart Highlights
CJC-1295 DAC (Drug Affinity Complex) is a long-acting GHRH analogue investigated for its ability to elevate GH and IGF-1 for extended periods following subcutaneous administration. This guide presents a clear, unit-based dilution plan using a 5 mg vial.
- Once-weekly schedule : is typical due to ~6–8 day half-life in humans.
- Standard start : 0.5–1.0 mg once weekly; Advanced: up to 2.0 mg once weekly or split twice weekly.
- Reconstitution : Use ≤3 mL total. For ease of measuring, this page uses 3.0 mL (standard) or 2.5 mL (advanced).
- Storage : Lyophilized at ≤−20 °C (≤−4 °F); reconstituted at 2–8 °C (36–46 °F), protected from light.
- Product image : below • Product ID: 13371
Dosing & Reconstitution Guide
Educational guide for reconstitution and dosing protocol (5 mg vial, max 3 mL diluent)
Standard / Gradual Approach (3.0 mL = 1.667 mg/mL)
| PHASE | DOSAGE (MCG) | UNITS (PER INJECTION) |
|---|---|---|
| Weeks 1–4 | 0.5 mg (1× weekly) | 30 units (0.30 mL) |
| Weeks 5–8 | 1.0 mg (1× weekly) | 60 units (0.60 mL) |
| Weeks 9–12 (Optional) | 1.5 mg (1× weekly) | 90 units (0.90 mL) |
Why 3.0 mL? It keeps per-injection units comfortably above ~10u for precision. Note that 2.0 mg at this dilution equals 120 units (1.20 mL) which exceeds a 1 mL insulin syringe; consider the Advanced approach or split the dose.
- Draw 3.0 mL bacteriostatic water with a sterile syringe (do not exceed 3 mL).
- Inject slowly down the vial wall; allow powder to dissolve. Swirl gently—do not shake.
- Label concentration (1.667 mg/mL), date, and store at 2–8 °C (36–46 °F), protected from light.
Advanced / Aggressive Approach (2.5 mL = 2.0 mg/mL)
| PHASE | DOSAGE (MCG) | UNITS (PER INJECTION) |
|---|---|---|
| Weeks 1–4 | 1.0 mg (1× weekly) | 50 units (0.50 mL) |
| Weeks 5–8 | 1.5 mg (1× weekly) | 75 units (0.75 mL) |
| Weeks 9–12 | 2.0 mg (1× weekly) | 100 units (1.00 mL) |
| Alternative (Weeks 9–12) | 1.0 mg twice weekly (e.g., Mon/Thu) = 2.0 mg/wk | 50 units (0.50 mL) each injection |
Why 2.5 mL? It allows high-end doses (2.0 mg) to fit within a single 1 mL (100-unit) insulin syringe while keeping lower doses ≥25 units for practical measuring. Do not exceed a total of 3 mL per vial.
- Draw 2.5 mL bacteriostatic water and reconstitute as above.
- Label concentration (2.0 mg/mL), date, and refrigerate at 2–8 °C (36–46 °F).
Protocol Overview
Concise summary of a once-weekly regimen suitable for long-acting GHRH analogue research.
- Primary Aim : Characterize GH/IGF-1 dynamics with long-acting GHRH stimulation
- Schedule : Once weekly for 8–12 weeks (longer extensions possible)
- Dose Range : 0.5–2.0 mg weekly depending on study design
- Reconstitution : 3.0 mL (1.667 mg/mL) for standard titration; 2.5 mL (2.0 mg/mL) for higher weekly doses
- Storage : Lyophilized ≤−20 °C; reconstituted 2–8 °C; avoid repeated freeze–thaw
Dosing Protocol
Once-weekly research framework with optional split dosing.
- Start : 0.5–1.0 mg once weekly (see Standard table)
- Escalation : Up to 1.5–2.0 mg once weekly (Advanced table)
- Split option : For 2.0 mg/week, consider 1.0 mg twice weekly (e.g., Mon/Thu)
- Timing : Maintain consistent weekly timing to control for circadian variation
Storage Instructions
Proper storage supports peptide integrity during studies.
- Lyophilized : ≤−20 °C (≤−4 °F), dry, protected from light
- Reconstituted : 2–8 °C (36–46 °F); prepare aliquots to avoid freeze–thaw cycles
- Handling : Allow vial to reach room temp before opening to minimize moisture uptake
Suppilies Needed
Approximate quantities for an 8–16 week research cycle.
- Peptide Vials (5 mg each):
• At 1.0 mg/week: 8 wks ≈ 2 vials, 12 wks ≈ 3 vials, 16 wks ≈ 4 vials
• At 2.0 mg/week: 8 wks ≈ 4 vials, 12 wks ≈ 5–6 vials, 16 wks ≈ 7–8 vials
- Insulin Syringes (1 mL, 100-unit) : 1 per planned injection
- Bacteriostatic Water : 10 mL vials (allow extra for multiple vials/reconstitutions)
- Alcohol Swabs: 1 box
Important Notes
- Max reconstitution volume per vial is 3 mL.
- Record concentration, lot numbers, and dates on vial labels and in study logs.
- If your calculated dose ever falls below ~10 units, consider smaller insulin syringes (50-unit or 30-unit) for accuracy.
How This Works
CJC-1295 DAC is a modified GHRH (1-29) analogue that bioconjugates to endogenous serum albumin via its DAC moiety, prolonging circulation time and enabling sustained stimulation of pituitary GHRH receptors.
- Albumin binding : DAC linkage increases apparent half-life to ~6–8 days.
- Endocrine effects : Studies in healthy adults show dose-dependent rises in GH (2–10×) for ~6+ days and IGF-1 for ~9–11 days; repeated dosing kept IGF-1 above baseline up to 28 days.
- Pulsatility : GH pulse frequency is preserved, with elevated trough GH contributing to overall exposure.
Potential Research Observations & Considerations
- Sustained GH/IGF-1 elevations consistent with long-acting GHRH analogues
- Commonly reported tolerability signals in studies: mild injection-site reactions, flushing, headache; no serious adverse events reported in early healthy-volunteer trials cited below
- General peptide handling: minimize freeze–thaw; aliquot reconstituted solutions; protect from light
Study Design & Controls
- Keep injection day/time consistent; standardize fasting status and activity around sampling
- Log concomitant compounds and timing to control confounders
- Use consistent anatomical injection sites and rotation patterns
Injection Technique
General subcutaneous technique (education only):
- Clean stopper and site with alcohol; allow to dry
- Pinch subcutaneous tissue; insert at ~45° into fatty tissue; inject slowly
- Rotate sites (abdomen, thigh, triceps area) to minimize local irritation
Recommended Source
We recommend Go Alpha Labs for high-purity CJC-1295 DAC (5 mg).
Why Go Alpha Labs?
- Independent lab verification targeting ≥99% purity
- Transparent quality documentation and rigorous handling
- Reliable fulfillment for research timelines (USA only)
Compliance Notice:
For Research Use Only. Not for human or veterinary use. This page is educational and does not provide medical advice.
References:
For Research Use Only. Not for human or veterinary use. This page is educational and does not provide medical advice.
| Source | Link |
|---|---|
| J Clin Endocrinol Metab (2006) – CJC-1295 human RCT: half-life ~5.8–8.1 days; GH/IGF-1 responses; repeated dosing up to 28 days | View Source |
| J Clin Endocrinol Metab (2006) – GH pulsatility preserved after CJC-1295; elevated trough GH | View Source |
| Endocrinology (2005) – hGRF(1-29) albumin bioconjugates; identification of CJC-1295; albumin binding confirmed | View Source |
| PMC Review (2023) – Serum albumin as a half-life extender (bioconjugation principles) | View Source |
| PMC Review (2021) – Albumin-binding domains prolong plasma half-life of biologics | View Source |
| Drug Test Anal. (2021) – Detection of GHRH analogs incl. CJC-1295 (metabolites; analytical context) | View Source |
| J Clin Endocrinol Metab (1996) – GHRH infusions enhance GH pulsatility (context for GHRH-class agents) | View Source |
| Sigma-Aldrich – Peptide handling & storage guidelines (lyophilized ≤−20 °C; avoid freeze–thaw) | View Source |
| Bachem – Handling & storage guidelines for peptides (hygroscopicity; handling) | View Source |
| GenScript – Peptide storage and handling (−20 °C storage; light protection; oxidation risks) | View Source |
| CDC – Vaccine Administration – Subcutaneous injection angle & site (general technique) | View Source |
| WHO Toolkit – Injection safety best practices (sterility; preparation) | View Source |
| Immunize.org – Subcutaneous injection technique one-pager | View Source |
| PMC (2009) – Review of GH/IGF-1 axis activation by GHRH analogues incl. CJC-1295 | View Source |